期刊文献+

哌拉西林钠他唑巴坦钠致大疱表皮松解型药疹一例

A case of epidermolysis bullosa drug eruption caused by piperacillin sodium and tazobactam sodium
下载PDF
导出
摘要 目的探讨患者发生大疱表皮松解型药疹的起因。方法梳理患者的诊疗经过,通过药物筛查、不良反应发生时间关联情况进行分析,探讨患者发生严重药品不良反应的原因。结果可疑药物包括泮托拉唑肠溶胶囊、哌拉西林钠他唑巴坦钠,经关联性评价对可疑药物的判断分别为“可能”、“很可能”。结论哌拉西林钠他唑巴坦钠致大疱表皮型松解型药疹属非常罕见,易被忽略,应引起临床重视。 Objective To investigate the causes of epidermolysis bullosa drug eruption in patients.Methods The diagnosis and treatment process of the patients was sorted out,and the correlation between drug screening and adverse drug reaction time was analyzed to explore the causes of serious adverse drug reactions in patients.Results The suspicious drugs included pantoprazole enteric-coated capsules,piperacillin sodium and tazobactam sodium,which were judged as"possible"and"probable"respectively after correlation evaluation.Conclusion The epidermolysis of bullae caused by piperacillin sodium and tazobactam sodium is very rare,easy to be ignored,and should be paid attention to in clinic.
作者 农莉 苏棋 莫凯 张慧玲 秦艳娥 蓝晓步 NONG Li;SU Qi;MO Kai(The First People’s Hosipital of Nanning,Nanning Guangxi 530022,China)
出处 《中国处方药》 2022年第5期51-52,共2页 Journal of China Prescription Drug
基金 2020年广西药品监督管理局局直属单位药品安全科研项目计划。
关键词 哌拉西林钠他唑巴坦钠 大疱表皮松解型药疹 药品不良反应 Piperacillin sodium and tazobactam sodium Epidermolysis bullosa drug eruption Adverse drug reaction
  • 相关文献

参考文献5

二级参考文献32

  • 1王侠生,孙清娟.重症药疹104例临床分析[J].临床皮肤科杂志,1993,22(4):187-189. 被引量:58
  • 2王侠生,李慎秋,方丽华.大疱性表皮坏死松解型药疹──43例回顾性研究[J].临床皮肤科杂志,1994,23(6):311-313. 被引量:34
  • 3林赴田.他唑巴克坦与哌拉西林联用的药理和临床[J].中国新药杂志,1996,5(4):265-270. 被引量:11
  • 4Odom RB,Jams WD,Berger TG,et al.Andrews'diseases of the skin clinical dermatology,9th ed[C].Harcourt Asia:Saunders,2001,138.
  • 5Bastuji-Garin S, Rzany B, Stem RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol, 1993, 129 ( 1 ): 92-96.
  • 6Bastuji-Garin S, Fouchard N, Bertocehi M, et al. SCORTEN: a severity of illness score for toxic epidermal neerolysis. J Invest Dermatol, 2000, 115(2): 149-153.
  • 7Imahara SD, Holmes JH, Heirnbaeh DM, et al. SCORTEN Overestimates Mortality in the Setting of a Standardized Treatment Protocol. J Burn Care Res, 2006, 27(3 ): 270-275.
  • 8Cartotto R, Mayich M, Nickerson N, et al. SCORTEN Accurately Predicts Mortality Among Toxic Epidermal Neerolysis Patients Treated in a Burn Center. J Bum Care Res, 2008, 29 (1): 141-146.
  • 9Guegan S, Bastuji-Garin S, Poszepczynska-Guigne E, et al. Performance of the SCORTEN During the First Five Days of Hospitalization to Predict the Prognosis of Epidermal Necrolysis. J Invest Dermatol, 2006, 126(2): 272-276.
  • 10Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States. Arch Dermatol, 2004, 140(7): 890- 892.

共引文献116

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部